News
Print
May 25, 2010
Place: NASDAQ MarketSite
4 Times Square, NYC
(43rd and Broadway)
Time: 10:00 a.m. EDT | Date: June 1, 2010
Meeting RSVP: meeting2010@advaxis.com or the Advaxis facebook portal
_________________________________________________
*** SHAREHOLDER PROXY VOTES DUE MAY 27, 2010 ***
Proxy RSVP: www.SHAREHOLDERMATERIAL.com/ADXS
North Brunswick, NJ – May 25, 2010 – Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, invites common stock shareholders and other interested parties to the 2010 Advaxis Annual General Meeting of shareholders (AGM).
Following the formal portion of the AGM, Advaxis Chairman/CEO Thomas A. Moore will provide an update on Company initiatives including the status of the Advaxis clinical trial program that include three (3) Phase II and one (1) Phase I in cervical cancer (2), cervical dysplasia (1) and head and neck cancer (1), respectively.
All shareholders not attending the AGM are encouraged to mail in their proxy votes as soon as possible as votes must be received no later than May 27, 2010. As an added convenience, investors can cast their vote on-line at:
www.SHAREHOLDERMATERIAL.com/ADXS.
For security purposes at the Nasdaq MarketSite, all investors attending the AGM are required to RSVP no later than May 27, 2010 at: meeting2010@advaxis.com or find us on facebook and accept meeting invite.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.
Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn
